Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer
Turning Point Therapeutics, Inc. - Common stock (TPTX)
Last turning point therapeutics, inc. - common stock earnings: 3/16 09:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
In TKI-naïve ROS1+ Patients, Overall Response Rate by Blinded Review is 82 Percent, and 83 Percent at Likely Recommended Phase 2 Dose of 160 mg QD or Above; Median Duration of Response across all Dose Levels Not Yet ReachedSince Prior Update, Overall Response Rate by Blinded Review Increased in ROS1+ Patients Pretreated with one Prior TKI to 39 percent and to 55 Percent at Doses of 160 mg QD or Above All Five ROS1+ Crizotinib-Pretreated Patients with G2032R Solvent Front Mutation had Tumor Regressions, and Overall Response Rate by Blinded Review is 40 Percent Phase 2 Portion of TRIDENT-1 Registrational Study on Track for Initiation in 2H 2019 Company Files 10-Q and Provides Financial Update SAN DIEGO, May 31, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced updated interim data from its ongoing Phase 1/2 TRIDENT-1 clinical study of lead drug candidate repotr
Show less
Read more
Impact Snapshot
Event Time:
TPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TPTX alerts
High impacting Turning Point Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics